Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis

Araújo, Iasmin Aparecida Cunha; Paula, Renata Cristina de; Alves, Ceres Luciana; Faria, Karen Ferraz; Oliveira, Marco Miguel de; Mendes, Gabriela Gonçalves; Dias, Eliane Martins Ferreira Abdias; Ribeiro, Raul Rio; Oliveira, Alaı́de Braga de; Silva, Sydnei Magno da

doi:10.1016/j.exppara.2019.02.013

Cited by 38 publications

(17 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Leishmaniasis is a treatable and curable disease, but drugs that used in treatment have several limitations because of serious side effect ( World Health Organization (WHO), 2018 ; Araújo et al, 2019 ). The results showed that the secondary metabolite inhibited the growth of promastigote forms, a fact observed by Santiago et al (2012) that isolated 564 endophytic fungi from plants of the Antarctic, these 19 sources leishmanicidal activity against a promastigote form of L. amazonensis .…”

Section: Discussionmentioning

confidence: 99%

Antimicrobial Potential of Streptomyces ansochromogenes (PB3) Isolated From a Plant Native to the Amazon Against Pseudomonas aeruginosa

et al. 2020

View full text Add to dashboard Cite

The objective of this study was to evaluate the antibacterial action of filamentous bacteria isolated from the Byrsonima crassifolia leaf. An endophytic bacterium has been identified by classical and molecular techniques as Streptomyces ansochromogene . Screening for antibacterial action against pathogens with medical relevance ( Klebsiella pneumoniae ATCC 700603, Pseudomonas aeruginosa ATCC 15692, Staphylococcus aureus ATCC 6538, Corynebacterium diphtheriae ATCC 27012, Mycobacterium abscessus , Cryptococcus gattii ATCC 24065, and Cryptococcus neoformans ATCC 24067) demonstrated activity against the bacterium P. aeruginosa ATCC 0030 with inhibition diameter zones (IDZ) of 17.6 ± 0.25 mm in the preliminary screening in solid medium. After fermentation in liquid medium, an IDZ of 19.6 ± 0.46 mm and a minimum inhibitory concentration (MIC) of 0.5 mg/mL were detected. The antibiofilm action was observed with 100% inhibition of biofilm formation at a concentration of 0.250 mg/mL. When the infection curve was prepared, it was observed that the metabolite was effective in protecting the larvae of Tenebrio molitor . The metabolite does not show toxicity for eukaryotic cells. The leishmanicidal activity demonstrated that the metabolite presented a dose-dependent effect on the promastigotes forms of Leishmania amazonensis growth and the estimated IC 50 /72 h was 71.65 ± 7.4 μg/mL. Therefore, it can be concluded that the metabolite produced by the endophytic bacterium Streptomyces sp. is promising for future use as an alternative strategy against bacterial resistance.

show abstract

Section: Discussionmentioning

confidence: 99%

Antimicrobial Potential of Streptomyces ansochromogenes (PB3) Isolated From a Plant Native to the Amazon Against Pseudomonas aeruginosa

et al. 2020

View full text Add to dashboard Cite

show abstract

“…UA was solubilized in DMSO and further PBS (never exceeding 1% DMSO); and AmB was solubilized in sterile water. The highest doses of 1.0 and 5.0 mg/kg from AmB and UA, respectively, were selected based on previously published works [ 21 , 45 , 46 ].…”

Section: Methodsmentioning

confidence: 99%

“…Forty BALB/c mice (four weeks old; weight ~ 25 g) were inoculated at the base of the tail with 2 × 10 7 promastigote forms of L. amazonensis in stationary phase of growth (final volume 25 µL) as described in previous published works [ 9 , 46 , 47 , 48 , 49 ]. Five healthy control group was injected only with physiological solution.…”

Section: Methodsmentioning

confidence: 99%

Ursolic Acid Potentializes Conventional Therapy in Experimental Leishmaniasis

et al. 2020

View full text Add to dashboard Cite

Ursolic acid (UA) is a triterpene with a broad array of pharmacological activities. In leishmaniasis, UA killed different species of parasites, and it was active in the experimental model of cutaneous and visceral leishmaniasis. Thus, the objective of this work was to study the therapeutic efficacy of the conventional drugs amphotericin B (AmB) or glucantime (Glu) combined with UA in experimental visceral and cutaneous leishmaniasis, respectively. L. (L.) infantum-infected hamsters were treated with AmB alone or combined with UA. L. (L.) amazonensis-infected BALB/c mice were treated with Glu alone or combined with UA. Animals were treated for 15 consecutive days by intraperitoneal or intralesional routes. Following one week after the last dose, the tissue parasitism and cellular immune responses were analyzed. Hamsters treated with 0.2 and 1.0 mg/kg of AmB plus 1.0 mg/kg of UA showed low hepatic and splenic parasitisms; however, AmB given as monotherapy did not reduce the number of viable parasites in the spleen of treated animals. In cutaneous leishmaniasis, Glu given as monotherapy was inactive at 2.0 mg/kg, showed mild activity at 10.0 mg/kg, and at 50.0 mg/kg was highly active at eliminating parasites in the skin. When animals were treated with Glu plus UA, higher leishmanicidal activity was observed in comparison to all groups treated with monotherapy schemes, and such activity was related to lesion improvement and upregulation of IFN-γ production. Altogether, data suggest that the association of drugs for the treatment of leishmaniasis can increase the efficiency of the treatment and decrease the toxicity associated to the conventional drugs.

show abstract

“…Some products of natural origin showed not very encouraging results. Lapachol showed promising in vitro antileishmanial activity against the promastigote forms and intracellular amastigote forms of L. infantum (IC 50 135.79 and 171.26 μM, respectively), with a high selectivity index (Araújo et al, 2019). However, in murine VL models, oral treatment with lapachol (25 mg/kg/day) reduced the hepatic parasitic load and splenic lesions by 4.6 and 5.3 times, respectively.…”

Section: Resultsmentioning

confidence: 99%

Recent strategies for the development of oral medicines for the treatment of visceral leishmaniasis

Souza

Costa

Silva

et al. 2020

Drug Development Research

View full text Add to dashboard Cite

Considered prevalent in many countries on five continents, especially in low‐income regions, leishmaniasis is a neglected tropical disease classified by World Health Organization as one of the diseases for which the development of new treatments is a priority. It is an infectious disease caused by protozoa of the genus Leishmania, whose species may cause different clinical manifestations, such as cutaneous and visceral leishmaniasis (VL). Treatment is exclusively by drug therapy, as it has not been possible to develop vaccines yet. Currently available drugs are not fully effective in all cases; they have parenteral administration and exhibit a number of serious and very common adverse effects. The only oral drug available is expensive and it is not available in many endemic countries. Injectable administration is the main problem of treatments, since it requires patients to go to health centers, hospitalization and professional administration, which are conditions that are not adapted to the reality of the poverty conditions of patients with the disease. In this context, the development of an oral medicine has become a focus as it may solve many of these issues. Based on this scenario, this review aimed to investigate which therapeutic alternatives have been studied for the development of oral drugs directed to the treatment of human VL.

show abstract

Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis

Cited by 38 publications

References 47 publications

Antimicrobial Potential of Streptomyces ansochromogenes (PB3) Isolated From a Plant Native to the Amazon Against Pseudomonas aeruginosa

Antimicrobial Potential of Streptomyces ansochromogenes (PB3) Isolated From a Plant Native to the Amazon Against Pseudomonas aeruginosa

Ursolic Acid Potentializes Conventional Therapy in Experimental Leishmaniasis

Recent strategies for the development of oral medicines for the treatment of visceral leishmaniasis

Contact Info

Product

Resources

About